دورية أكاديمية
أعرض في EDS

Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus disease.

التفاصيل البيبلوغرافية
العنوان: Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus disease.
المؤلفون: Singh S; Department of Medicine, University of Texas School of Medicine, Tyler, Texas, USA., Wang JY; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan., Heysell SK; Division of Infectious Diseases and International Health, University of Virginia, USA., McShane PJ; Section of Pulmonary and Critical Care, University of Texas at Tyler, Tyler, Texas, USA., Wadle C; Section of Pulmonary and Critical Care, University of Texas at Tyler, Tyler, Texas, USA., Shankar P; Department of Medicine, University of Texas School of Medicine, Tyler, Texas, USA., Huang HL; Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan., Pasipanodya J; Quantitative Preclinical & Clinical Sciences Department, Praedicare Inc., Dallas, Texas., Boorgula GD; Department of Medicine, University of Texas School of Medicine, Tyler, Texas, USA., Philley JV; Section of Pulmonary and Critical Care, University of Texas at Tyler, Tyler, Texas, USA., Gumbo T; Quantitative Preclinical & Clinical Sciences Department, Praedicare Inc., Dallas, Texas; Hollow Fiber System & Experimental Therapeutics Laboratories, Praedicare Inc, Dallas, TX., Srivastava S; Department of Medicine, University of Texas School of Medicine, Tyler, Texas, USA; Department of Cellular and Molecular Biology, University of Texas Health Science Center at Tyler, Tyler, Texas, USA; Center for Biomedical Research, University of Texas Health Science Centre at Tyler, Tyler, Texas, USA. Electronic address: Shashi.kant@uthct.edu.
المصدر: International journal of antimicrobial agents [Int J Antimicrob Agents] 2023 Jul; Vol. 62 (1), pp. 106847. Date of Electronic Publication: 2023 May 13.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 9111860 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7913 (Electronic) Linking ISSN: 09248579 NLM ISO Abbreviation: Int J Antimicrob Agents Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Amsterdam : Elsevier Science Publishers, c1991-
مواضيع طبية MeSH: Mycobacterium abscessus* , Mycobacterium Infections, Nontuberculous*/drug therapy , Lung Diseases*/drug therapy, Humans ; Retrospective Studies ; Anti-Bacterial Agents/therapeutic use ; Anti-Bacterial Agents/pharmacology ; Tetracyclines/therapeutic use ; Tetracyclines/pharmacology ; Microbial Sensitivity Tests
مستخلص: Background: Guideline-based therapy (GBT) for pulmonary Mycobacterium abscessus (Mab) disease achieves sustained sputum culture conversion (SSCC) rates of 30%; this is reflected by poor efficacy of GBT in the hollow fiber system model of Mab (HFS-Mab), which killed ∼1.22 log 10 CFU/mL. This study was performed to determine which clinical dose of omadacycline, a tetracycline antibiotic, should be used in combination therapy to treat pulmonary Mab disease for relapse-free cure.
Methods: First, omadacycline intrapulmonary concentration-time profiles of seven daily doses were mimicked in the HFS-Mab model and exposures associated with optimal efficacy were identified. Second, 10,000 subject Monte-Carlo simulations were performed to determine whether oral omadacycline 300 mg/day achieved these optimal exposures. Third, a retrospective clinical study on omadacycline vs. primarily tigecycline-based salvage therapy was conducted to assess rates of SSCC and toxicity. Fourth, a single patient was recruited to validate the findings.
Results: Omadacycline efficacy in the HFS-Mab was 2.09 log 10 CFU/mL at exposures achieved in >99% of patients on 300 mg/day omadacycline. In the retrospective study of omadacycline 300 mg/day-based combinations vs. comparators, SSCC was achieved in 8/10 vs. 1/9 (P=0.006), symptom improvement in 8/8 vs. 5/9 (P=0.033), toxicity in 0 vs. 9/9 (P<0.001), and therapy discontinuation due to toxicity in 0 vs. 3/9 (P<0.001) cases, respectively. In one prospectively recruited patient, omadacycline 300 mg/day salvage therapy achieved SSCC and symptom-resolution in 3 months.
Conclusion: Based on the preclinical and clinical data, omadacycline 300 mg/day in combination regimens could be appropriate for testing in Phase III trials in patients with Mab pulmonary disease.
(Copyright © 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.)
References: Front Pharmacol. 2021 Dec 08;12:790767. (PMID: 34955859)
J Antimicrob Chemother. 2022 May 29;77(6):1694-1705. (PMID: 35257162)
Clin Infect Dis. 2020 Aug 14;71(4):e1-e36. (PMID: 32628747)
ERJ Open Res. 2021 Feb 15;7(1):. (PMID: 33614773)
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6374-6. (PMID: 27458221)
Open Forum Infect Dis. 2020 Sep 09;7(10):ofaa415. (PMID: 33094118)
Antimicrob Agents Chemother. 2017 Oct 24;61(11):. (PMID: 28807911)
Antimicrob Agents Chemother. 2021 Feb 17;65(3):. (PMID: 33288634)
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0170421. (PMID: 34662184)
Int J Infect Dis. 2022 Sep;122:953-956. (PMID: 35798234)
Antimicrob Agents Chemother. 2016 May 23;60(6):3779-85. (PMID: 27067317)
Clin Infect Dis. 2011 Mar 1;52(5):572-4. (PMID: 21292660)
J Infect Dis. 2015 Jun 15;211 Suppl 3:S96-S106. (PMID: 26009618)
J Antimicrob Chemother. 2019 Jun 1;74(6):1607-1617. (PMID: 30820554)
Antimicrob Agents Chemother. 2015 Dec 07;60(3):1242-8. (PMID: 26643339)
Clin Infect Dis. 2018 Nov 28;67(suppl_3):S267-S273. (PMID: 30496455)
Antimicrob Agents Chemother. 2019 May 24;63(6):. (PMID: 30962331)
Front Microbiol. 2018 Feb 13;9:67. (PMID: 29497402)
J Antimicrob Chemother. 2019 Oct 1;74(10):2930-2933. (PMID: 31236595)
J Antimicrob Chemother. 2020 May 1;75(5):1212-1217. (PMID: 32016429)
Antimicrob Agents Chemother. 2016 Apr 22;60(5):2895-900. (PMID: 26926649)
Cureus. 2019 Jul 9;11(7):e5112. (PMID: 31523543)
Antimicrob Agents Chemother. 2017 Aug 24;61(9):. (PMID: 28696233)
J Antimicrob Chemother. 2017 Sep 01;72(suppl_2):i3-i19. (PMID: 28922813)
Open Forum Infect Dis. 2021 Jan 07;8(2):ofab002. (PMID: 33628856)
Clin Infect Dis. 2012 Jul;55(2):169-77. (PMID: 22467670)
Clin Infect Dis. 2013 Jul;57(1):21-31. (PMID: 23487389)
Antimicrob Agents Chemother. 2019 Apr 25;63(5):. (PMID: 30858221)
معلومات مُعتمدة: R01 AI137080 United States AI NIAID NIH HHS; R21 AI148096 United States AI NIAID NIH HHS; U01 AI150508 United States AI NIAID NIH HHS
فهرسة مساهمة: Keywords: Efficacy; Hollow fiber system model; M. abscessus; Pharmacokinetics/pharmacodynamics; Safety
المشرفين على المادة: 090IP5RV8F (omadacycline)
0 (Anti-Bacterial Agents)
0 (Tetracyclines)
تواريخ الأحداث: Date Created: 20230515 Date Completed: 20230619 Latest Revision: 20240702
رمز التحديث: 20240702
مُعرف محوري في PubMed: PMC10330927
DOI: 10.1016/j.ijantimicag.2023.106847
PMID: 37187338
قاعدة البيانات: MEDLINE
الوصف
تدمد:1872-7913
DOI:10.1016/j.ijantimicag.2023.106847